Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.

摘要: BACKGROUND Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement outcome. To the authors' knowledge, validated predictive biomarkers for exist, although emerging data suggest that subsets APCA may benefit from treatment bevacizumab. The authors evaluated baseline serum albumin (b-alb) as a biomarker pooled analysis 7 prospective clinical trials gemcitabine-based therapy or without bevacizumab. METHODS Data were collected individual databases trials. Patients grouped by exposure to and b-alb level (≥ 3.4 g/L or < 3.4 g/dL). Overall survival (OS), time disease progression (TTP), overall response rate, control rate (overall plus stable lasting ≥ 16 weeks) compared between groups. Univariate multivariable analyses prognostic factors performed. RESULTS A total 264 included. median age was 59 years (range, 31 years-85 years) all had stage IV per TNM staging. Normal associated significantly improved OS (10.2 months vs 4.1 months; P = .0001), TTP (6.2 3.7 P = 0.0488), (71% 46%; P = .007) receiving bevacizumab, but not those treated Multivariable revealed significant influence normal on (P = .0008) (P = .033). CONCLUSIONS Patients derive Future investigations should consider selecting maximize potential benefit. Cancer 2014;120:1780–1786. © 2014 American Society.